The efficacy of bromhexine hydrochloride in the prevention of COVID-19 disease
- Conditions
- COVID-19.COVID_19U07.1
- Registration Number
- IRCT20200317046797N7
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 3500
18 Years to 80 years old
Both genders
Having household contact or contact in less than 1.5 meters for more than one hour, or exposed without facemask with a COVID-19 case confirmed with RT-PCR or with clinical or radiographic evidence of pneumonia, acute respiratory distress syndrome (ARDS)
Free of the COVID-19 disease symptoms (fever, cough, dyspnea, difficulty breathing, sore throat, severe fatigue, headache, GI symptoms)
Free from chronic respiratory or other illnesses with symptoms confused with symptoms of COVID-19 disease
Signed consent form
Less than 18 years
Severe renal failure
Severe liver disease
Pregnant or breastfeeding woman or with a positive pregnancy test result
Subjects on immune-modulating drugs for other diseases
subjects on other clinical trials for COVID-19 within 30 days before or after randomization
Subjects in other drug clinical trial
Having an allergy to bromhexine hydrochloride or its ingredients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Test for the presence or absence of corona virus nucleic acid. Timepoint: 15 days after the intervention. Method of measurement: Real-time PCR.;Serum levels of IgM and IgG. Timepoint: 15 days after the intervention. Method of measurement: Immunological test.
- Secondary Outcome Measures
Name Time Method